1Verheugt FWA, Meijer A, Lafrand WK, et al. Reocclision : the flip side of coronary thrombolysis. J Am Coll Cardiol, 1996,27:766 - 773
2Kwon K, Freedman SB, Wilcox I, et al. The unstable ST segment early after thrombolysis and its usefulness as a marker of recurrent coronary occlusion. Am J Cardiol,1993 ,88 :437 -446
3Ridker PM, O' Donnell C, Marder VJ, et al. Large - scale trial of thrombolytic therapy for acute myocardial infarction : GISSI - 2, ISIS - 3,and GUSTO - 1. Ann Intern MED,1993 ,119 :530 -532
4Brouwer MA,van den Bergh PJ,Aengevaeren WR, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction : results of the Antithrembotics in the Prevention of Reocclusion In Coronary Thrembolysis (APRICOT) - 2 Trial. Circulation ,2002,106:659 - 665
5Mahaffey KW, Granger CB, Collins R, et al. Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. Am J Cardiol, 1996, 77:551 - 556
6Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low - molecular - weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Repedusion Therapy (HART Ⅱ). Circulation, 2001, 104 : 648 - 652
7Bonaa KH, Arnesen E. Association beween heart rate and athero-genic blood lipid fractions in a population. The Tromso study[J] Circulation, 1992,86 (2) : 394-405.
8Glass GV. Primary, secondary, and meta analysis of research[J] Edu Res,1976,6(5) :3.
